SCHEMBL4530808

SCHEMBL4530808

CCNC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.63
RAB9A P51151 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
DRD2 P14416 2/20 0.62
DRD4 P21917 2/20 0.62
DRD3 P35462 2/20 0.62
EPHX2 P34913 1/20 0.60
NR1H4 Q96RI1 1/20 0.60
CTDSP1 Q9GZU7 1/20 0.60
HDAC3 O15379 2/20 0.58
HDAC1 Q13547 2/20 0.58
HDAC2 Q92769 2/20 0.58
HDAC8 Q9BY41 2/20 0.58
HDAC4 P56524 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19734509 1.00 NPC1 (0.63) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL27934347 0.94 GAA (0.61) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL13714817 0.89 EPHX2 (0.60) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL162323 0.88 GAA (0.68) NPC1RAB9ASMN1; SMN2EPHX2HDAC3
Hydrochloric Acid SCHEMBL3581933 0.86 GAA (0.65) NPC1RAB9ASMN1; SMN2EPHX2HDAC3
Hydrochloric Acid SCHEMBL27504812 0.86 GAA (0.65) NPC1RAB9ASMN1; SMN2EPHX2HDAC3
SCHEMBL11337226 0.86 GAA (0.65) NPC1RAB9ASMN1; SMN2EPHX2HDAC3
SCHEMBL11337298 0.86 GAA (0.65) NPC1RAB9ASMN1; SMN2EPHX2HDAC3
SCHEMBL11335914 0.86 GAA (0.65) NPC1RAB9ASMN1; SMN2EPHX2HDAC3
SCHEMBL5909057 0.85 CA12 (0.58) NPC1RAB9AHDAC3HDAC1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3341007-B1 MALT1 INHIBITORS AND USES THEREOF UNIV CORNELL (US) 2020-12-23 EP disclosed
CN-103265442-B Novel pleuromutilin derivatives, as well as preparation method and anti-tumour application thereof 北京理工大学 2017-02-08 CN disclosed
WO-2016183359-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. (US) 2016-11-17 WO disclosed
US-20160266133-A1 NUCLEIC ACID-SCAFFOLDED SMALL MOLECULE LIBRARIES ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2016-09-15 US disclosed
WO-2015050505-A1 BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-04-09 WO disclosed
CN-103265442-A Novel pleuromutilin derivatives, as well as preparation method and anti-tumour application thereof BEIJING INST TECHNOLOGY 2013-08-28 CN disclosed
US-8084615-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2011-12-27 US disclosed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-20090299063-A1 Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses Therefor NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-12-03 US disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-20090163496-A1 ANTIBACTERIAL AGENTS UNIVERSITY OF WASHINGTON (US) 2009-06-25 US disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 NPC1 2180/4885RAB9A 2498/4885SMN1; SMN2 1840/4885
US-20160266133-A1 NUCLEIC ACID-SCAFFOLDED SMALL MOLECULE LIBRARIES SNRPE, SARNP, SARS1 NPC1 2440/4885RAB9A 3601/4885SMN1; SMN2 1887/4885
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX NPC1 1477/4885RAB9A 2708/4885SMN1; SMN2 4398/4885
US-20090163496-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS NPC1 371/4885RAB9A 557/4885SMN1; SMN2 2296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.